

INVESTMENT STRATEGY:

The Perimeter Small Cap Growth Fund is managed according to the investment process employed by the Perimeter Capital investment management team since 1998. The goal of the Fund is to maintain a broadly diversified portfolio of small cap stocks that has an optimal combination of earnings growth and fundamental characteristics. The investment team seeks companies that are expected to outperform, not only in strong growth markets, but during any market environment. The consistent application of the team's sell discipline is also an integral part of the historical success of the overall process.

Under normal circumstances, the Fund invests at least 80% of its net assets in small-cap equity securities. The Fund defines small-cap equity securities as those companies with a market capitalization between \$50 million and \$2 billion at the time of purchase. The Fund's investments will generally consist of U.S.-traded securities, which may include American Depositary Receipts (ADRs) among other types of securities.


Fund Facts

Ticker:	PSCGX
CUSIP:	00764Q843
Fund Inception:	9/29/2006
# of Holdings:	209
Expense Ratio (Gross):	1.40%
Expense Ratio (Net):	1.35% [◇]
Redemption Fee:	2% < 7 days
Net Assets (3/2010):	\$164.7M


Portfolio Distribution

Market Cap Range (in \$ millions)	% of Portfolio
0 - \$300	12.73%
\$300 - \$750	30.54%
\$750 - \$1,500	32.45%
\$1,500 - \$3,000	23.52%
\$3,000+	0.76%

Investment Style



Sector Weightings




Top 10 Holdings*

Company	Ticker	Fund
Salix Pharmaceuticals Ltd.	SLXP	0.94%
VIVUS Inc.	VVUS	0.88%
Compuware Corp.	CPWR	0.85%
Syniverse Holdings Inc.	SVR	0.85%
Solera Holdings Inc.	SLH	0.84%
Encore Capital Group Inc.	ECPG	0.78%
Par Pharmaceutical Cos. Inc.	PRX	0.76%
Old Dominion Freight Line Inc.	ODFL	0.74%
99 Cents Only Stores	NDN	0.73%
Medicis Pharmaceutical Corp.	MRX	0.72%

* Holdings are subject to change.

Performance Results**



** The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by calling 1-888-968-4964.

◇ The Adviser has contractually agreed to waive fees and/or reimburse expenses in order to limit expenses through December 31, 2011. Without these limitations performance would have been lower. Under certain circumstances, advisor may waive redemption fee.

Please see the "Performance of Comparable Account" section of the prospectus for information pertaining to the performance of similar accounts managed by the Adviser.

The past performance of the comparable account is no guarantee of the future performance of the Fund.

● Fund Inception Date 9/29/2006



Perimeter Small Cap Growth Fund

Investor Shares

June 30, 2010

Manager Commentary

The quarter started off strong with most indices reaching 52-week highs by late April, only to see a sharp reversal as weakening economic data raised the specter of a double-dip recession. Housing statistics turned downward shortly after the expiration of the first time home buyers tax credit, and employment statistics showed a lack of improvement, as corporations and small businesses have been hesitant to add jobs. Furthermore, with the spreading sovereign debt crisis and the massive oil spill in the Gulf of Mexico, it is not surprising that consumer and investor sentiment turned negative during the quarter. The fear and caution were evident in stock performance as every sector in the benchmark declined in 2Q10, with the Consumer Discretionary and Energy sectors posting the most severe pullbacks. Even relative safe havens like Consumer Staples and Utilities posted negative returns, albeit to a lesser degree than the rest of the market.

Healthcare was Perimeter's top relative contributor to performance in the quarter given strong stock selection within the Pharmaceuticals industry. Salix Pharmaceuticals received FDA approval for a new indication for its gastrointestinal drug Xifaxan while VIVUS Inc. continued to make progress towards approval of a new obesity drug, Qnexa; propelling both stocks higher. Likewise, the portfolio benefited from good stock selection in Energy along with our very limited exposure to offshore oil service companies that have seen a decline in activity as a result of the oil spill. Offsetting the above were weaker selection within the Technology sector, particularly the Communication Equipment and Internet Software areas, as well as weak selection in the more economically sensitive Materials sector.

The second quarter of 2010 was difficult for the markets, especially considering the Russell 2000 Growth Index has fallen over 18% from the late April 2010 highs (as of this writing on 7/6/10). The markets are likely to continue to experience a higher level of volatility over the ensuing months as consumers and investors digest the current economic landscape and evidence of a slowdown. We maintain a positive bias for the full year but recognize that job creation and combating deflation is a key component in this outlook. Regardless, we expect our style of investment management, with a focus on higher quality companies that should be able to sustain growth in the future, will fare well in this type of uncertain market.

- Mark D. Garfinkel, CFA

FINANCIAL TERMS:

Total Return - All performance calculations are total returns. Total return is comprised of dividend and interest income, realized and unrealized gains and losses.

Estimated Annual Income - An estimate of the dividends and interest to be received over the next twelve months based on current asset allocation and information.

Russell 2000 Growth Index - Measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values. The Russell 2000 is comprised of the smallest 2000 companies of the Russell 3000. One cannot invest directly in an index.

Alpha - measure of risk-adjusted performance.

Beta - measure of risk in relation to the market or benchmark

Standard Deviation - statistical measure of historical volatility; a measure of the extent to which numbers are spread around their average.

Information Ratio - the ratio of expected return to risk, as measured by standard deviation.

Tracking Error - the amount by which the performance of the portfolio differed from the benchmark

R² - measure of how closely a portfolio's performance correlates with the performance of a benchmark index.



Portfolio Characteristics

	Perimeter Fund	Russell 2000 Growth Index
Price/Earnings	19.3x	20.9x
Est. EPS Growth	11.6%	2.9%
Return on Equity	10.1%	7.6%
LT Debt/Capital	22.6%	27.1%
Market Capitalization (in \$MM)	\$1,032.9	\$973.1

MPT Statistics

	Perimeter Composite	Russell 2000 Growth Index
Alpha	1.08	0.00
Beta	0.95	1.00
Standard Deviation	21.71	22.77
Information Ratio	0.38	--
Sharpe Ratio	-0.02	-0.07
R ²	0.98	1.00

For the 5-Year Period Ending 6/30/2010

Source: eVestment Alliance

MPT Statistics are calculated on the Perimeter U.S. Small Cap Growth composite. Gross of fees.

DISTRIBUTOR:

The Perimeter Small Cap Growth Fund is distributed by BNY Mellon Distributors Inc., which is not affiliated with the Adviser.

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and other information can be found in the Fund's prospectus, which may be obtained by calling 1-888-968-4964 or by visiting www.perimetercap.com. Read the prospectus carefully before investing. There are risks involved with investing, including possible loss of principal. In addition to the normal risks associated with investing, investments in smaller companies typically exhibit higher volatility. Current and future holdings are subject to risk

This material represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events, or a guarantee of future results. This information should not be relied upon by the reader as research or investment advice regarding the fund or any stock in particular. There is no assurance that the securities listed will remain in or out of the fund after the date of this material.